What Can You Expect in 2026?
Marking its 10th anniversary, the Liquid Biopsy for Precision Oncology Summit is the world’s leading meeting dedicated to advancing liquid biopsy across discovery, development and delivery. Over the past decade, the field has seen ctDNA and MRD transform from exploratory assays into powerful clinical tools, with multi-omic approaches, methylation profiling, AI, and fragmentomics now unlocking unprecedented insights.
As liquid biopsy moves closer to routine clinical adoption, standardization now stands as one of the greatest challenges: from aligning definitions and analytical thresholds, to building the evidence regulators, payers and clinicians need for confidence.
The 2026 agenda responds directly to this call, bringing together leaders from pharma, biotech, diagnostics, academia, advocacy and policy to define solutions that accelerate validation, reimbursement and access.
First-time Perspectives from Organizations New to the Conversation
Session Spotlights
Celebrating 10 Years of Liquid Biopsy Innovation
At our landmark anniversary meeting, celebrate a decade of breakthroughs with a retrospective keynote and future vision session from Bristol Myers Squibb
MRD Moves from Promise to Proof
Take MRD beyond detection, with sessions on regulatory qualification, payer alignment and adoption as a surrogate endpoint in solid tumors
Driving Standardization
Participate in interactive sessions led by BLOODPAC on shared definitions, metrics, and thresholds to finally enable reliable, scalable global adoption
Beyond ctDNA & Beyond Cancer
Hear cutting-edge presentations on AI, fragmentomics, and methylation, alongside the first-ever focus on liquid biopsy in Alzheimer’s
Bigger Stage, Bigger Network
Convening 250+ leaders spanning pharma, diagnostics, policy and payers makes this the largest and broadest summit yet
Specialized Content, Bespoke to Your Needs
Plenary Talks
Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology
Steffan Ho, Vice President – Translational Medicine, Pfizer
Conference Day One
Translating MRD into Regulatory Evidence: Defining the Approval & Adoption Pathway in Solid Tumors
Claudia Dollins, Vice President – Regulatory Affairs, GSK
Conference Day Two
Preclinical & Early Translational
Leveraging Mutation & Methylation-Based ctDNA Profiling to Capture Tumor Heterogeneity & Enhance Clinical Readouts
Anneleen Daeman, Executive Director of Translational Medicine, ORIC Pharmaceuticals
Conference Day One
From Assay to Action – Making MRD a Practical Tool for Treatment Decisions in Hematology
Yanwen Jing, Distinguished Scientist, Genentech
Conference Day Two
Clinical Development & Commercialization
Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies
Cedric Dos Santos, Global Product Leader, AstraZeneca
Conference Day One
Navigating the Complex, Uncertain Regulatory Environment to Expedite Global Patient Access to Liquid Biopsy Testing
Michelle Neff, Associate Vice President - Global Regulatory Affairs, Diagnostics & Companion Diagnostics, Eli Lilly
Conference Day Two
Explore the Full Event Agenda Now
- 40+ expert speakers sharing cutting-edge insights
- 12 hours of dedicated networking including 1-to-1 meetings and receptions
- 4 workshops and engagers with leading innovators
- 2 focused tracks covering discovery to adoption
- Full information on attending stakeholders across pharma, biotech, diagnostics, academia, and advocacy
Attending Companies Include
Explore the Full Agenda
Dive into 2 tracks and 4 workshops led by 40+ expert speakers shaping the future of liquid biopsy
Prioritize Partnering With Us
Showcase your solutions, connect with decision-makers, and position your company as the go-to provider in precision oncology
Join 250+ Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and patient voices driving real-world adoption